Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trial

Antagonist Therapy ◽

Factor Antagonist ◽

Pseudotumoral Colonic Tuberculosis Complicating Rheumatoid Arthritis Treated with a Tumor Necrosis Factor Antagonist

American Journal of Roentgenology ◽

10.2214/ajr.05.0412 ◽

2006 ◽

Vol 186 (6) ◽

pp. 1799-1800 ◽

Cited By ~ 2

Author(s):

Alvian Lesnik ◽

Julie Bolivar ◽

Jacques Morel ◽

Patrice Taourel

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Colonic Tuberculosis ◽

Factor Antagonist ◽

Refractory Lymphocytic Enterocolitis and Tumor Necrosis Factor Antagonist Therapy

Clinical Gastroenterology and Hepatology ◽

10.1016/j.cgh.2009.12.010 ◽

2010 ◽

Vol 8 (4) ◽

pp. 391-394 ◽

Cited By ~ 7

Author(s):

Ghazaleh Aram ◽

Theodore M. Bayless ◽

Zong–Ming Chen ◽

Elizabeth A. Montgomery ◽

Mark Donowitz ◽

...

Keyword(s):

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Antagonist Therapy ◽

Factor Antagonist ◽

National Practice Patterns in Tuberculosis and Hepatitis Screening Prior to Tumor Necrosis Factor Antagonist Therapy in Veterans with Inflammatory Bowel Disease

The American Journal of Gastroenterology ◽

10.14309/00000434-201310001-01789 ◽

2013 ◽

Vol 108 ◽

pp. S539

Author(s):

Jason Hou ◽

Jennifer Kramer ◽

Peter Richardson ◽

Shubhada Sansgiry ◽

Hashem El-Serag

Keyword(s):

Inflammatory Bowel Disease ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Practice Patterns ◽

Antagonist Therapy ◽

Inflammatory Bowel ◽

National Practice ◽

Factor Antagonist ◽

PMS9 Biologic Therapy Patterns and Associated Costs in Rheumatoid Arthritis Patients Who Initiated a Tumor Necrosis Factor Antagonist Over Two Years

Value in Health ◽

10.1016/j.jval.2012.03.198 ◽

2012 ◽

Vol 15 (4) ◽

pp. A35 ◽

Cited By ~ 3

Author(s):

H. Wang ◽

Y. Wang ◽

T. Michael ◽

B. Hopkins ◽

M. Bodoria ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Biologic Therapy ◽

Factor Antagonist ◽

Sa1723 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Crohn's Disease: A Multicenter Consortium Propensity Score-Matched Analysis

Gastroenterology ◽

10.1016/s0016-5085(18)31547-6 ◽

2018 ◽

Vol 154 (6) ◽

pp. S-369-S-370 ◽

Cited By ~ 1

Author(s):

Matthew Bohm ◽

Sashivar Sagi ◽

Monika Fischer ◽

Siri Kadire ◽

Gloria Tran ◽

...

Keyword(s):

Crohn’S Disease ◽

Tumor Necrosis Factor ◽

Crohn's Disease ◽

Propensity Score ◽

Comparative Effectiveness ◽

Tumor Necrosis ◽

Antagonist Therapy ◽

Factor Antagonist ◽

328 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Ulcerative Colitis: A Multicenter Consortium Propensity Score-Matched Analysis

Gastroenterology ◽

10.1016/s0016-5085(18)30723-6 ◽

2018 ◽

Vol 154 (6) ◽

pp. S-82 ◽

Cited By ~ 1

Author(s):

David Faleck ◽

Preeti Shashi ◽

Joseph Meserve ◽

Mahmoud Rahal ◽

Siri Kadire ◽

...

Keyword(s):

Ulcerative Colitis ◽

Tumor Necrosis Factor ◽

Propensity Score ◽

Comparative Effectiveness ◽

Tumor Necrosis ◽

Antagonist Therapy ◽

Factor Antagonist ◽

G320(P) Adenosine deaminase 2 deficiency with a novel variant of CECR1 gene mutation: responding to tumor necrosis factor antagonist therapy

10.1136/archdischild-2020-rcpch.276 ◽

2020 ◽

Author(s):

B Almoosawi ◽

Z Almusawi ◽

Hiba Omar ◽

B Maryam

Keyword(s):

Tumor Necrosis Factor ◽

Adenosine Deaminase ◽

Gene Mutation ◽

Tumor Necrosis ◽

Antagonist Therapy ◽

Novel Variant ◽

Adenosine Deaminase 2 ◽

Factor Antagonist ◽

277 - Comparative Safety Profile of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy for Inflammatory Bowel Disease: A Multicenter Consortium Propensity Score-Matched Analysis

Gastroenterology ◽

10.1016/s0016-5085(18)30684-x ◽

2018 ◽

Vol 154 (6) ◽

pp. S-68 ◽

Cited By ~ 3

Author(s):

Dana J. Lukin ◽

Aaron Weiss ◽

Satimai Aniwan ◽

Siri Kadire ◽

Gloria Tran ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Tumor Necrosis Factor ◽

Propensity Score ◽

Tumor Necrosis ◽

Antagonist Therapy ◽

Inflammatory Bowel ◽

Comparative Safety ◽

Factor Antagonist ◽

284 Tuberculosis and Hepatitis B Reactivation Are Rare After Treatment With Tumor Necrosis Factor Antagonist Therapy Among Patients With Inflammatory Bowel Disease

Gastroenterology ◽

10.1016/s0016-5085(15)30213-4 ◽

2015 ◽

Vol 148 (4) ◽

pp. S-61

Author(s):

Jason K. Hou ◽

Jennifer R. Kramer ◽

Peter Richardson ◽

Shubhada Sansgiry ◽

Hashem B. El-Serag

Keyword(s):

Inflammatory Bowel Disease ◽

Tumor Necrosis Factor ◽

Hepatitis B ◽

Bowel Disease ◽

Tumor Necrosis ◽

Antagonist Therapy ◽

Inflammatory Bowel ◽

Factor Antagonist ◽

Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2005.11.1089 ◽

2006 ◽

Vol 54 (3) ◽

pp. S122-S126 ◽

Cited By ~ 34

Author(s):

Paul S. Yamauchi ◽

Logan Turner ◽

Nicholas J. Lowe ◽

Vivian Gindi ◽

J. Mark Jackson

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Sweet’S Syndrome ◽

Sweet's Syndrome ◽

Factor Antagonist ◽